<DOC>
	<DOCNO>NCT02449109</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy nano drug（Gemzar® mix Compound Glycyrrhizin Injection） interventional therapy use digital subtraction angiography（DSA） liver cancer .</brief_summary>
	<brief_title>Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） Liver Carcinoma</brief_title>
	<detailed_description>By enrol patient liver cancer adapt enrolled criterion , study document first time safety short long term efficacy nano drug interventional therapy use digital subtraction angiography（DSA）for liver cancer . The nano drug make mix Gemzar® Compound Glycyrrhizin Injection . The nano drug 's size detect laser diffraction particle size analyzer .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Age:1880 2 . Karnofsky performance status &gt; 60 3 . Diagnosis liver cancer base histology current accept radiological measure . 4 . Classification tumor , node , metastasisclassification ( TNM ) stage : Ⅱ , Ⅲ , Ⅳ 5 . Will receive interventional therapy 6 . Life expectancy : Greater 3 month 7 . Patients ' routine blood test , liver function kidney function obvious abnormality 8 . Ability understand study protocol willingness sign write informed consent document 1 . Patients primary tumor except liver cancer 2 . History coagulation disorder anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Liver Cancer</keyword>
	<keyword>Nano drug</keyword>
</DOC>